Stock Price Quote

SMS PHARMACEUTICALS LTD.

NSE : SMSPHARMABSE : 532815ISIN CODE : INE812G01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE211.35-2.6 (-1.22 %)
PREV CLOSE ( ) 213.95
OPEN PRICE ( ) 218.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 19691
TODAY'S LOW / HIGH ( )209.95 218.75
52 WK LOW / HIGH ( )75.1 219.3
NSE211.35-2.85 (-1.33 %)
PREV CLOSE( ) 214.20
OPEN PRICE ( ) 214.95
BID PRICE (QTY) 211.35 (2972)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 192959
TODAY'S LOW / HIGH( ) 209.95 216.70
52 WK LOW / HIGH ( )79.4 219.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-12 1987
Management Info
Ramesh Babu Potluri - Chairman Ramesh Babu Potluri - Managing Director
Registered Office

Address Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. Sbi Executive Enclave,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 2525 9999

Email info@smspharma.com

Website www.smspharma.com

Registrars Details
Aarthi Consultants Pvt Ltd
1-2-285 ,Domalaguda,,Hyderabad
Listing : BSE, NSE

NEWS

21Mar SMS Pharmaceuticals informs about disc
SMS Pharmaceuticals has informed that the exchange has received the disc..
21Mar SMS Pharmaceuticals informs about disc
SMS Pharmaceuticals has informed that it enclosed the disclosure under R..
08Feb Allotment of Convertible warrants
Preferential Issue of shares Inter alia, approved:- 1. The Board Cons..
08Feb Allotment of Equity Shares
Preferential Issue of shares Inter alia, approved:- 1. The Board Cons..
05Feb Allotment of Equity Shares
Quarterly Results & Preferential Issue of shares & Inter-alia shall also..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit121.7240.8499999999988
Gross Profit 164.07 55.4999999999987
Operating Profit 303.69595.899999999999
Net Sales 1614.825220.51

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  827.60 (8.15%)
M.Cap ( in Cr)390.76
Mankind Pharma (BSE)
peergroup  2393.90 (2.40%)
M.Cap ( in Cr)95896.87
Torrent Pharma (BSE)
peergroup  2636.30 (1.76%)
M.Cap ( in Cr)89224.37
Ajanta Pharma (BSE)
peergroup  2135.80 (2.17%)
M.Cap ( in Cr)26893.07
Strides Pharma Scien (BSE)
peergroup  890.20 (5.24%)
M.Cap ( in Cr)8180.91

Shareholding Pattern

PROMOTERS 64.67%
NON-INSTITUTION 33.17%
MUTUAL FUNDS/UTI 1.98%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About SMS Pharmaceuticals Ltd.

SMS Pharmaceuticals Ltd. was incorporated in the year 1987. Its today's share price is 211.35. Its current market capitalisation stands at Rs 1789.12 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5526.86 Cr and Total Income of Rs.5269.37 Cr. The company's management includes T Neelaveni, P Sarath Kumar, Vamsi Krishna Potluri, Sarvepalli Srinivas, Shravan Kudaravalli, Ramesh Babu Potluri , Ramesh Babu Potluri , Thirumalesh Tumma.

It is listed on the BSE with a BSE Code of 532815 , NSE with an NSE Symbol of SMSPHARMA and ISIN of INE812G01025. It's Registered office is at Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. Sbi Executive Enclave,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are P Murali & Co, Rambabu & Co, Suryanarayana & Suresh

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.